Compare Definium Therapeutics Inc. Common Shares (DFTX) vs F5 Inc (FFIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs F5 Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while F5 Inc trades at $460.99 (market cap $26.42B). The key difference: F5 Inc is far larger — about 5.6× Definium Therapeutics Inc. Common Shares's market cap, and F5 Inc is trading nearer its 52-week high, Definium Therapeutics Inc. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and F5 Inc for 38 Days on average.
| DFTX | FFIV | |
|---|---|---|
Market Cap | $4.71B | $26.42B |
Volume | 1,966,636 | 454,868 |
Sector | Health | Technology |
52-Week High | $48.45 | $469.79 |
52-Week Low | $10.68 | $223.99 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $3.67B | $25.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
F5 (FFIV) trades at $466.65, down 0.67% on the day, as the stock consolidates near recent highs following strong year-to-date performance. The company continues to demonstrate robust fundamentals with revenue growth accelerating to $3.09 billion in 2025 and net income reaching $692 million, representing a 22.4% margin. Recent analyst recognition as a leader in WAAP platforms and AI security positions F5 well in the growing cybersecurity market. Technical indicators show the stock trading near resistance at $468 with bullish moving averages but overbought RSI readings suggesting potential near-term consolidation.
F5 presents a compelling growth story with consistent earnings beats and expanding profitability, though current valuation multiples appear elevated. The main investment opportunity lies in the company's leadership in application security and AI-driven solutions, while risks include competitive pressures and execution challenges in maintaining growth momentum. Analyst consensus remains cautiously optimistic with a $416.60 price target, indicating potential downside from current levels despite the positive business trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
